Riociguat is a medication used in the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It is classified as a soluble guanylate cyclase stimulator, which means that it works by stimulating the production of cyclic guanosine monophosphate (cGMP), leading to vasodilation and improved blood flow. Riociguat is often used in combination with other medications to effectively treat PAH and CTEPH.
Chemical Name
The chemical name of Riociguat is 1-(4,6-diamino-2,5-dihydro-1,3,5-triazin-2-yl)-4-[2-fluoro-4-[(6-methoxypyridin-3-yl)methylamino]phenyl]-1H-pyrazol-5-ol.
Molecular Formula
The molecular formula of Riociguat is C20H19F2N9O.
Formula Weight
The formula weight of Riociguat is 422.44 g/mol.
CAS No
The CAS number for Riociguat is 625115-55-1.
Top Ten Keywords from Google and Synonyms
Synonyms:
Health Benefits of this Product
Riociguat is an effective medication for the treatment of PAH and CTEPH. By stimulating the production of cGMP, it leads to vasodilation and improved blood flow in the lungs, resulting in reduced symptoms and improved exercise capacity for individuals with PAH and CTEPH.
Potential Effects
In addition to its primary function of treating PAH and CTEPH, Riociguat has some potential additional effects that may be beneficial for individuals with these conditions. These include:
Improved survival: Riociguat has been shown to improve survival rates for individuals with PAH compared to placebo.
Reduced hospitalizations: Riociguat has been associated with reduced hospitalizations for individuals with PAH and CTEPH.
Improved quality of life: Riociguat has been shown to improve quality of life for individuals with PAH and CTEPH, leading to increased physical activity and decreased symptoms.
Product Mechanism
Riociguat works by stimulating the production of cGMP, which leads to vasodilation and improved blood flow in the lungs. By binding to the heme moiety of the soluble guanylate cyclase enzyme, Riociguat increases the sensitivity of the enzyme to nitric oxide (NO), leading to increased production of cGMP.
By increasing cGMP levels, Riociguat leads to relaxation of smooth muscle cells in the pulmonary arteries, improving blood flow and reducing symptoms associated with PAH and CTEPH.
Safety
Riociguat is generally considered safe and well-tolerated. However, like all medications, it can cause side effects in some individuals. Common side effects of Riociguat include headache, dizziness, nausea, and diarrhea.
Rare but serious side effects of Riociguat include pulmonary hemorrhage, systemic hypotension, and acute kidney injury. Patients should seek medical attention immediately if they experience any of these symptoms while taking Riociguat.
Dosing Information
The recommended starting dose of Riociguat is 1 mg three times daily, with dose adjustments made based on individual response and tolerability. Riociguat should be taken with food to improve absorption. Riociguat is often used in combination with other medications to effectively treat PAH and CTEPH.
Conclusion
Riociguat is an effective medication for the treatment of PAH and CTEPH. It works by stimulating the production of cGMP, leading to vasodilation and improved blood flow in the lungs, resulting in reduced symptoms and improved exercise capacity for individuals with PAH and CTEPH. Riociguat has potential additional benefits, including improved survival, reduced hospitalizations,
